Impact of insulins glulisine and aspart on postprandial glycemia after a high-glycemic index meal in children with type 1 diabetes

What Was Tested

The paper reports a study of Insulin Aspart, published as a randomized controlled trial.

According to current knowledge, glulisine insulin (GLU) has a slightly faster onset of action than aspart (ASP) insulin.

Therefore, GLU might lead to a better postprandial profile than ASP following the consumption of high-glycemic index (H-GI) meals.

The aim of this study was to assess differences in the action of GLU and ASP after the consumption of a H-GI meal in type 1 diabetic children treated with insulin pumps.

Who Took Part

PubMed indexes the participants as children and teenagers, both men and women.

FIFTY-SIX TYPE 1 DIABETIC CHILDREN OF MEAN AGE 14.72.0 YEARS WERE INCLUDED IN A RANDOMIZED, DOUBLE-BLIND, TWO-WAY CROSSOVER STUDY.

How the Study Was Run

In design terms this was a randomized, double-blind and crossover study.

The participants were allocated by chance, so the Insulin Aspart group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Insulin Aspart, so expectations could not easily colour the readings.

Each person switched between Insulin Aspart and the comparison at some point, usually with a gap in between.

They were given a H-GI breakfast for two subsequent days.

The primary outcome was postprandial glycemia (PPG) based on continuous glucose monitoring system and self monitoring of blood glucose levels during 3 h of follow-up.

The secondary outcomes were the frequency of hypoglycemia, glucose area under the curve, mean amplitude of glycemic excursion, and glycemic rise.

What Was Measured

The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 1, Glycemic Index, Hyperglycemia, Hypoglycemic Agents, Insulin and Insulin Aspart.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Aspart.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2014 (European journal of endocrinology), a journal based in England.

More context: the Insulin Aspart compound page.